Lindy Durrant, Scancell CEO

Giv­ing first glimpse of da­ta, Scan­cell looks for Covid-19 vac­cine part­ner

UK-based biotech Scan­cell is lift­ing the veil off a Phase I tri­al for its Covid-19 vac­cine, but it’ll al­so be mak­ing a piv­ot on the vac­cine’s strat­e­gy.

Scan­cell said in a re­lease on Mon­day that it is pre­sent­ing the pre­lim­i­nary da­ta from its Phase I clin­i­cal tri­al, which was con­duct­ed at the Uni­ver­si­ty of Cape Town Lung In­stitue in South Africa. The tri­al was in­tend­ed to look at two of vac­cine Scan­cell’s can­di­dates, SCOV1 and SCOV2, in pa­tients be­fore test­ing them as a boost­er. Ac­cord­ing to the biotech, both can­di­dates are plas­mid DNA-based vac­cines.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.